Network Bio has raised $50.0M, a fresh infusion of capital for a startup that’s betting AI can read human tissue the way it reads text. The company’s pitch is straightforward: train models on the world’s largest patient tissue dataset, tie that to blood samples and clinical outcomes from top US academic biobanks, and see if medicine gets sharper.
The round lands with existing backers S32, Thiel Bio, Founders Fund, Blue Venture Fund, and Breyer Capital already in the fold. What stands out isn’t just the size-it’s the premise. Most AI in healthcare leans on claims data or scans. Network Bio is going deeper, into the cellular level, and that’s where the real diagnostic edge might live. No word yet on how the cash will be deployed, but the ambition is clear.
